CA2252505C - Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires - Google Patents

Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires Download PDF

Info

Publication number
CA2252505C
CA2252505C CA002252505A CA2252505A CA2252505C CA 2252505 C CA2252505 C CA 2252505C CA 002252505 A CA002252505 A CA 002252505A CA 2252505 A CA2252505 A CA 2252505A CA 2252505 C CA2252505 C CA 2252505C
Authority
CA
Canada
Prior art keywords
apcs
cells
antigen
lymphocytes
histamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002252505A
Other languages
English (en)
Other versions
CA2252505A1 (fr
Inventor
Mohamed Chokri
Jacques Bartholeyns
Jean-Loup Romet-Lemonne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IDM Immuno Designed Molecules
Original Assignee
IDM Immuno Designed Molecules
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP96401099A external-priority patent/EP0808897A1/fr
Application filed by IDM Immuno Designed Molecules filed Critical IDM Immuno Designed Molecules
Publication of CA2252505A1 publication Critical patent/CA2252505A1/fr
Application granted granted Critical
Publication of CA2252505C publication Critical patent/CA2252505C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

L'invention concerne des cellules présentant l'antigène dérivées des monocytes (MD-APC), caractérisées par les propriétés suivantes: elles présentent à leur surface les antigènes CD14 et CD64 avec une intensité moyenne comprise entre 5 et 200 environ, les antigènes CD80 et CD86 avec une intensité moyenne comprise entre 20 et 200 environ, l'antigène CD40 et le récepteur du mannose avec une intensité moyenne comprise entre 50 et 500; elles sont sensiblement dépourvues des antigènes de surface CD1a et CD1c; elles présentent une propriété de phagocytose; elles présentent la propriété de stimuler la prolifération de lymphocytes allogènes.
CA002252505A 1996-05-21 1997-05-15 Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires Expired - Fee Related CA2252505C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96401099A EP0808897A1 (fr) 1996-05-21 1996-05-21 Cellules présentant l'antigène, procédé de leur fabrication et leur utilisation comme des vaccins cellulaires
EP96401099.5 1996-05-21
PCT/EP1997/002703 WO1997044441A1 (fr) 1996-05-21 1997-05-15 Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires

Publications (2)

Publication Number Publication Date
CA2252505A1 CA2252505A1 (fr) 1997-11-27
CA2252505C true CA2252505C (fr) 2006-04-18

Family

ID=36250937

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002252505A Expired - Fee Related CA2252505C (fr) 1996-05-21 1997-05-15 Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires

Country Status (1)

Country Link
CA (1) CA2252505C (fr)

Also Published As

Publication number Publication date
CA2252505A1 (fr) 1997-11-27

Similar Documents

Publication Publication Date Title
EP0925356B1 (fr) Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires
EP2058389B1 (fr) Milieu défini pour la maturation des cellules dendritiques comprenand TNF-alpha, IL-1beta, IL-6
US7198948B2 (en) Methods and compositions for obtaining mature dendritic cells
WO1997029182A9 (fr) Methodes et compositions pour obtenir des cellules dendritiques matures
Herbst et al. CD34+ peripheral blood progenitor cell and monocyte derived dendritic cells: a comparative analysis
JP3454825B2 (ja) 新規なマクロファージ、その製造方法、及び医薬組成物の活性物質としてのその用途
Pullarkat et al. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells
US20030124091A1 (en) Endothelial cell derived hematopoietic growth factor
Palucka et al. Lipopolysaccharide can block the potential of monocytes to differentiate into dendritic cells
Ratta et al. Efficient presentation of tumor idiotype to autologous T cells by CD83+ dendritic cells derived from highly purified circulating CD14+ monocytes in multiple myeloma patients
Chitta et al. GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells
Martinson et al. Activated platelets rapidly up-regulate CD40L expression and can effectively mature and activate autologous ex vivo differentiated DC
AU7867400A (en) Generation and characterization of a dendritic cell isolated from human peripheral blood mononuclear cells
US20030194395A1 (en) Th1 cell adoptive immunotherapy
US20040235162A1 (en) Method of preparing immunoregulatory dendritic cells and the use thereof
Citterio et al. Dendritic cells as natural adjuvants
US6051432A (en) Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
Rongcun et al. Interferon γ impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1a, CD80 and CD4
CA2252505C (fr) Nouvelles cellules presentant l'antigene, procede de preparation associe, et leur utilisation comme vaccins cellulaires
Feng et al. Development of mouse dendritic cells from lineage-negative c-kit< low pluripotent hemopoietic stem cells in vitro
Naderi et al. High expression of Fas ligand on cord blood dendritic cells: a possible immunoregulatory mechanism after cord blood transplantation
US6001351A (en) Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
EP0941309A1 (fr) Adjuvant cellulaire
US20230149523A1 (en) Treatment of autoimmunity and transplant rejection through establishment and/or promotion of tolerogenic processes by fibroblast-mediated reprogramming of antigen presenting cells
FR2796961A1 (fr) Procede d&#39;obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed